FORMULATION AND EVALUATION OF DOCETAXEL TRIHYDRATE LOADED SELF-ASSEMBLED NANOCARRIERS FOR TREATMENT OF HER2 POSITIVE BREAST CANCER by Rarokar, Nilesh Ramesh & Khedekar, Pramod Bhujangrao
 Rarokar et al                                                                                                              Journal of Drug Delivery & Therapeutics. 2017; 7(6):1-6                         
ISSN: 2250-1177                                                                              [1]                                                                            CODEN (USA): JDDTAO 
Available online on 15.11.2017 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open Access to Pharmaceutical and Medical Research 
© 2011-17, publisher and licensee JDDT, This is an Open Access article which permits unrestricted non-
commercial use, provided the original work is properly cited 
Open  Access                                                                                                                     Research Article 
FORMULATION AND EVALUATION OF DOCETAXEL TRIHYDRATE 
LOADED SELF-ASSEMBLED NANOCARRIERS FOR TREATMENT OF 
HER2 POSITIVE BREAST CANCER 
Nilesh R. Rarokar*, Pramod B. Khedekar
 
Nanotechnology Laboratory, Department of Pharmaceutical Sciences, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur, 
Maharashtra, India-440033 
 
ABSTRACT 
Human Epidermal Growth Factor Receptor 2-positive (HER2-positive) breast cancer tend to be more aggressive among all breast 
cancers. Breast cancers with HER2 gene amplification or HER2 protein overexpression are called HER2-positive. It tends to grow 
faster and are more likely to spread and come back compared to HER2-negative breast cancers. HER2 positive breast cancer is often 
treated with chemotherapy drugs called anthracylines (e.g. doxorubicine, epirubicine), taxanes (e.g. Docetaxel, peclitaxel) as well as 
some others, usually in combination of two or more chemotherapy drugs1 but the development of potential drug delivery system by 
using nanotechnology is also the important aspect for the proper treatment of HER2 positive breast cancer. The aim of this study was 
to develop DTX-loaded self assembled nanocarriers (SANs) for treatment of HER2 positive breast cancer and also to evaluate their 
efficacy to release the drug by controlled manner. SANs were prepared from a glyceryl monooleate, Pluronic® F127 (0.5 – 1.5 % 
w/v) and Pluronic® F68 (0.25-1.0 %w/v) in different concentration with or without docetaxel trihydrate (DTX) (2.0%w/v) by high 
pressure homogenization, before preparation compatibility of drug and polymers was studied by differential scanning calorimetry 
(DSC) and FTIR spectroscopy. Prepared SANs was then subject to different evaluation test particle size, zeta potential, % 
entrapment efficiency, drug content, in vitro drug release study, measurement of pH, and stability study. Particle size of SANs 
prepared with Pluronic® F127 was found in the range of 170 nm to 280 nm whereas SANs with Pluronic® F68 was found between 
200 to 240 nm and it shows more negative zeta potential value than -30 mV. More than 90 % of DTX was found to be entrapped in 
SANs formulations loaded with DTX 2.0% w/v. Drug released study revealed that formulation F9 containing 0.25% PF68 shows 
89.59 % release after 12 h and F5 containing 1.0% PF127 releases 96.56% drug after 12 h. Results of one month stability study 
shows that the SANs formulations were found to be stable over a one month. Hence, the DTX-loaded SANs was act as an potential 
drug carrier to fulfill the demand of cancer therapeutics. 
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INTRODUCTION  
Human Epidermal Growth Factor Receptor 2-positive 
(HER2-positive) breast cancer tend to be more 
aggressive among all breast cancers. Breast cancers 
with HER2 gene amplification or HER2 protein over 
expression are called HER2-positive.  The HER2 gene 
makes HER2 proteins. HER2 proteins are receptors on 
breast cells. Normally, HER2 receptors help control how 
a healthy breast cell grows, divides, and repairs itself. 
But in about 25% of breast cancers, the HER2 gene 
doesn't work correctly and makes too many copies of it 
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(known as HER2 gene amplification). All these 
extra HER2 genes tell breast cells to make too many 
HER2 receptors (HER2 protein over expression). This 
makes breast cells grow and divide in an uncontrolled 
way.  HER2-positive breast cancers tend to grow faster 
and are more likely to spread and come back compared 
to HER2-negative breast cancers. 
Between 15 and 25 out of every 100 women with breast 
cancer (15–25%) have HER2 positive cancers. 
Fewer men with breast cancer are thought to have HER2 
positive cancers. There are some treatments available 
specifically for HER2-positive breast cancer. There are 
different groups of chemotherapy drugs. HER2 positive 
breast cancer is often treated with chemotherapy drugs 
called anthracylines (e.g. doxorubicine, epirubicine), 
taxanes (e.g. Docetaxel, peclitaxel) as well as some 
others, usually in combination of two or more 
chemotherapy drugs
1
 but the development of potential 
drug delivery system by using nanotechnology is also 
the important aspect for the proper treatment of HER2 
positive breast cancer. There are number of 
nanoparticulate drug delivery system available for the 
delivery of anticancer agents but the Self-assembled 
nanocarriers (SANs) have more potential than the other 
drug delivery system. 
SANs are bicontinuous cubic phase liquid crystals have 
many properties that make them appealing as a universal 
vehicle for drug delivery. These are nanoparticles, more 
accurately nanostructure particles, or self-assembled 
liquid crystalline particles with a solid-like rheology
2
.  In 
recent years, SANs were considered as the drug 
nanocarrier due to their great potential as an alternative 
drug delivery system relative to liposome. The stability 
is another drawback in fabrication of liposome however 
colloidal dispersions of SANs can be stabilized by the 
addition of polymers. They also possess the potential for 
controlled delivery of actives, where diffusion is 
governed by the tortuous diffusion of the active through 
the “regular” channel structure of the cubic phase. SANs 
possess a sufficient average degree of molecular 
orientation in order to characterize by structural 
symmetry, and often form in aqueous surfactant system 
at relatively high ampiphile concentrations. 
SANs especially made of binary systems, monoolein–
water
3
. That can self-assemble into thermodynamically 
stable biocontinuous cubic liquid crystallize phases
4
. 
These are capable of loading lipophilic, hydrophilic, and 
amphiphilic drugs. Their three dimension nanostructure 
with hydrophobic and hydrophilic domains increases 
their importance in novel drug pharmaceutical drug 
delivery.  
These systems include liquid crystalline aggregates or 
cross-linked gel networks that load, stabilize and 
ultimately deliver active ingredients. Incorporation of 
drugs into the complex internal domains of these 
structures can facilitate diffusion controlled release of 
drug into the surrounding external aqueous 
environment
5–7
. The large interfacial area can provide a 
complex diffusion pathway for sustained release of 
entrapped drug molecules, whereas lipid constituents are 
biocompatible, bioadhesive, and digestible
8,
 
9
. 
The aim of this study was to develop DTX-loaded SANs 
for treatment of HER2 positive breast cancer and also to 
evaluate their efficacy to release the drug by controlled 
manner. 
MATERIALS AND METHOD 
Docetaxel trihydrate (DTX) was obtained as a gift 
sample from Scino Pharmaceutical Pvt., Taiwan. 
Glyceryl monooleate was obtained from Otto Chemie., 
Mumbai (India). Pluronic® F127 (PF127) obtained from 
Research Lab Fine Chem Industries, Mumbai(India), 
and Pluronic® F68 (PF68) was obtained from Himedia 
Laboratory Pvt. Ltd. Water was purifiedon a Milli-Q 
system obtained from a Millipore® synergy system 
(Millipore, Billerica, Massachusetts, USA). All other 
chemicals used were of analytical grade. 
Preparation of SANs 
SANs were prepared by method described in our 
previous publication
10 
from a glyceryl monooleate and 
Pluronic® F127 melt with or without drug. Glyceryl 
monooleate and Pluronic® F127 were melted at 60
°
C 
until homogenous at a ratio of glyceryl monooleate to 
Pluronic® F127 of 9:1 (w/w). DTX was loaded by 
preparing drug solution in required volume of ethanol 
for dissolution. To this mixture 5.0ml of ethanol was 
added as a hydrotropic solvent. 
To prepare the self-assembled nanocarriers dispersion, 
the low viscosity homogenous melt was either added 
drop wise or injected into excess water such that the 
concentration of lipid in the sample was approximately 
8–10% (w/w) with continuous stirring on magnetic 
stirrer and volume was made up to 100.0 ml with 
distilled water. Samples were allowed to equilibrate at 
room temperature for overnight. The samples were then 
homogenized for 2 min using homogenizer at 1500-2000 
rpm because much more homogenization may hamper 
the cubic crystal structure. Sterilization was done in 
autoclave at 121
°
C, 15lb pressure for 20 min. Prepared 
self-assembled nanocarriers dispersion stored in glass 
vial at room temperature. Same procedure was repeated 
for preparation of self-assembled nanocarriers with 
Pluronic® F68 as shown in Table. 1. Though Pluronic® 
have a gelling property, it does not show any type of 
gelation during self-assembled nanocarriers formation as 
it was used in very small concentration. 
Drug-Excipients Compatibility Studies 
Thermal Analysis 
The drug, the polymers, and their physical mixtures with 
DTX were analyzed by differential scanning calorimetry 
(DSC). Open pan DSC measurements were carried out 
using a DSC Q20 (TA Instruments Inc., New Castle, 
DE) with a sample size of approximately 5 mg weighed 
into each aluminum pans. Samples were heated at 10°C/ 
min from 0 to 400°C. Nitrogen at a flow rate of 40 mL/ 
min was used as a purge gas in DSC analyses. The 
results were analyzed using the Universal Analysis 
software version 4.5A; build 4.5.0.5 (TA Instruments, 
Inc., New Castle, DE, USA). 
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Table 1: SANs dispersion prepared with Pluronic F127 and Pluronic F68 
Sr. 
No. 
Formulation Glyceryle 
monooleate (% v/v) 
Pluronic F127       
(% w/v) 
Pluronic F68      
(% w/v)  
Ethanol   
(% v/v) 
DTX % 
(w/v) 
Dist. 
water 
01. F1 9.0 0.5 - 5.0 - q.s. 
02. F2 9.0 1.0 - 5.0 - q.s. 
03. F3 9.0 1.5 - 5.0 - q.s. 
04. F4 9.0 0.5 - 5.0 2.0 q.s. 
05. F5 9.0 1.0 - 5.0 2.0 q.s. 
06. F6 9.0 -  0.25 5.0 - q.s. 
07. F7 9.0 - 0.5 5.0 - q.s. 
08. F8 9.0 - 1.0 5.0 - q.s. 
09. F9 9.0 - 0.25 5.0 2.0 q.s. 
10. F10 9.0 - 0.5 5.0 2.0 q.s. 
*Value given for 100 mL 
 
FTIR Spectroscopy 
To determine any possible interactions, the physical 
mixtures of the drug and the polymers were analyzed 
using the Fourier transformed infrared (FTIR) 
spectroscopy. 
Briefly, the samples were dried in a hot air oven at 50°C 
for 2 h. The samples were mixed with KBr and subject 
to scanning in the range of 400 to 4000 cm−1. Infrared 
spectra of drug, polymer and their physical mixture were 
obtained from an FTIR spectrophotometer (Model: IR 
Prestige-21, Shimadzu, Japan) equipped with an 
attenuated total reflectance (ATR) accessory. The 
influence of the residual moisture was theoretically 
removed by subjecting the samples to vacuum drying 
before obtaining any spectra. Each sample analysis 
included 45 scans, at a resolution of 4 cm
−1
 from 4500 to 
400 cm
−1
. The shifts in the spectra of the drug in the 
presence of polymers and other components were 
investigated to determine physical interactions between 
the drug and the polymers, if any.
 
Evaluation of SANs 
Particle size determination
10
 
Particle size analysis of dispersions was performed using 
a Zeta sizer 3000 PCS (Malvern Instr., England) 
equipped with a 5 mW helium neon laser with a 
wavelength output of 633 nm. Measurements were made 
at 25
°
C, angle 90
°
, run time at least 40-80 sec and water 
used as a dispersant. Data interpreted by method of 
cumulants. 
Zeta potential measurement
10,
 
Zeta potential measurement of SANs dispersion was 
performed by using Zeta Potentiometer (Malvern Instr., 
England) equipped with a 5 mW helium neon laser with 
a wavelength output of 633 nm. Measurements were 
made at 25
°
C, angle 90
°
, 10-15 runs and water used as a 
dispersant.  
Entrapment efficiency
11
 
The sample of SANs dispersion was transferred to the 
centrifuge tubes and put to 1500 rpm for 2 h. Non-
entrapped drug or free drug in solution leaked outside 
the sub-tubes, making it possible to measure its 
concentration in solution, and thus allowed the 
deduction of the drug encapsulated in SANs. That UV 
absorbance was used to compute Ct (namely, total 
concentration) and the UV absorbance of DTX 
contained in filtrate after centrifuge was used to compute 
Cf (namely, filtrate concentration). Thus, the % 
entrapment efficiency was calculated as follows: 
% EE = [(Ct -Cf)/Ct] × 100 
Drug content of SANs
 11, 12
 
Each formulation (1.0 ml) equivalent to 20 mg was 
taken in a 100ml volumetric flask diluted with PBS (pH 
7.4) and shaken to until it gets dissolve otherwise 
sonicated for 30 min. The solution was filtered through 
whattman filter paper, 1 ml of above filtrate was pipette 
out and diluted to 10 ml with phosphate PBS (pH 7.4). 
The content of the drug was estimated 
spectrophotometrically by using standard curve plotted 
at 220 nm. 
In vitro drug release study 
11
 
Drug release from SANs dispersion was carried out by 
using Franz diffusion cell. It consists of two 
compartment i.e., Donor compartment (cell cap) and 
receptor compartment. Previously activated semi 
permeable membrane (cellophane membrane) is placed 
between these two compartments.  Dispersion was added 
into the donor compartment above cellophane 
membrane. Receptor compartment consist of stirring bar 
and sampling port having 18 ml capacity.  
The receptor compartment containing 18 ml PBS 
solution (pH 7.4) and maintained temperature at 37 + 0.5 
0
C at predetermined time points, 1ml of sample was 
withdrawn from the receptor compartment, replacing the 
sampled volume with same volume of PBS pH 7.4 after 
each sampling for a period of 10-12 h. The samples were 
suitably diluted and measured spectrophotometrically at 
220 nm. The concentration of drug was determined from 
a previously constructed calibration curve. 
 Determination of pH 
The pH of SANs dispersions was determined at room 
temperature using digital pH meter, model NIG-333. pH 
meter was calibrated using 9.2 pH and 4.0 pH buffer 
solutions. All the studies were repeated in triplicate with 
good agreement being found between measurements. 
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Stability study 
The stability study of selected formulation was done at 
40
0
C with 75% RH and room temperature and also in 
freezing temperature. The test parameters such as 
integrity, phase separation, pH measurement was carried 
out as a stability parameter after a specific time interval 
and drug precipitation were determined at every week 
till one month. Particle size determination was 
conducted at different time interval in order to evidence 
possible variations in mean diameter of SANs over time 
of one month. 
RESULT AND DISCUSSION  
Drug-Excipients Compatibility Studies 
Thermal Analysis 
The DSC thermogram of pure DTX showed a sharp 
endothermic peak at ∼169°C, corresponding to DTX 
melting point (thermograms not shown). Additionally, 
the DSC thermograms of Pluronic® F127 and Pluronic® 
F68 revealed sharp endothermic peaks at temperatures of 
∼58 and ∼56°C, respectively. 
The DSC analysis of the physical mixtures, DTX: 
Pluronic® F127 (1:1), and DTX: Pluronic® F68 (1:1), 
revealed a negligible and a non-significant change in the 
thermal behavior of DTX in the presence of these 
polymers. Additionally, the melting signals (endotherm) 
of Pluronic® F127, and Pluronic® F68 were clearly 
distinguishable in the physical mixtures of the respective 
polymers with DTX. The absence of any other 
endothermic peak over the entire temperature range thus 
excluded any physical interaction or obvious 
incompatibility between the drug and the polymers. The 
DSC results thus indicated the suitability of these 
polymers to be used in the prepared formulations.
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Figure1: DSC thermogram for DTX (A), physical mixture of DTX and polymers (B) 
 
Fourier Transform Infrared (FTIR) Spectroscopy 
The FTIR spectra for DTX, Pluronic® F127 and 
Pluronic® F68 individually, the binary mixtures of the 
drug with individual polymers, as well as a mixture of 
the drug with all the polymers, are shown in Fig. 2. The 
FTIR analysis did not show any significant difference 
between the individual spectra and those obtained from 
their physical mixtures. The results obtained after the 
FTIR study thus indicated that there was no positive 
evidence for the interaction between Docetaxel 
trihydrate and the used polymers. 
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(A) 
 
(B) 
 
(C) 
Figure 2: FTIR-spectra of DTX (A), DTX-Pluronic® F127 (B) and DTX-Pluronic® F68 (C) 
Evaluation of SANs  
Particle size 
Particle size of SANs F1 F2 F3 F4 F5 prepared by 
Pluronic® F127 in the concentration 0.5%, 1.0%, 1.5% 
without drug and 0.5%, 1.0% with drug DTX was found 
to be in the range of 170 nm to 280 nm. While Particle 
size of SANs F6, F7,  F8,  F9, F10 prepared by 
Pluronic® F68 in the concentration 0.25%, 0.5%,1.0%, 
1.5% without drug and 0.25% with drug DTX were 
found to be in the range of 200 nm to 240 nm. 
Zeta Potential  
Particles with zeta potentials more negative than -30mV 
are normally considered stable. The results of zeta 
potential measurement of SANs dispersion revealed that 
formulation F1 and F7 shows more negative zeta 
potential value about -54.1 mV and -47.4 mV 
respectively.  
Determination of pH 
Formulations F1, F2 , F3 , F4, F5 and F6, F7,  F8,  F9, 
F10 shows pH in the normal range of 6.5 to 7.5 whereas 
pH of formulation prepared by Pluronic® F68 (F6-F10 ) 
was found to be more than that of Pluronic® F127 (F1-
F5).  
Entrapment efficiency  
The drug entrapment efficiency is an important 
parameter for drug delivery systems. The % entrapment 
efficiency of the DTX loaded SANs was found to be 
95.67 ± 2.0, 94.74 ± 2.0 and 91.95 ± 1.8 (%w/w) for 
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formulations F4, F5 and F10   respectively. These results 
indicate that most of the DTX was encapsulated in the 
SANs.  
Drug content 
The results obtained in drug content determination for 
different formulations revealed that the drug content F4, F5 
and F10 was found to be more than 95% to the amount of 
drug loading. It means that, the entire drug was well 
uniformly distributed. The percentage relative standard 
deviation (% RSD) is less than 2% indicates the 
reproducibility of process used for further formulation. 
In vitro drug release study 
On the basis of results obtained during above evaluation 
parameters the formulations containing 1.0% Pluronic® 
F127 and 0.25% Pluronic® F68 were selected for the 
further study of drug release. The results of drug released 
study revealed that formulation F9 containing 0.25% PF68 
shows 89.59 % release after 12 h and F5 containing 1.0% 
PF127 releases 96.56% drug after 12 h, it means that 
formulation F9 prepared with 0.25 % Pluronic® F68 shows 
more sustained release as compared to F5 containing 1.0% 
PF 127 and might have efficiency to releases drug more 
than 12h however, plane DTX-solution shows complete 
release within 4h as shown in Figure 3. 
Stability Study  
The SANs dispersion prepared by both Pluronic® F127 and 
Pluronic® F68 appears milky white and odorless. After 
production and elimination of large particles by filtration, 
dispersion was stored in glass vials at room temperature in 
dark, 40
°
C with 75% RH and also at freezing temperature. 
In order to assess the physical stability of SANs dispersion, 
organoleptic and morphological aspects such as phase 
separation and formation of precipitates were investigated 
as a function of time. The organoleptic and morphological 
aspects of SANs dispersion were found to be unchanged 
with time; and SANs dispersion was found to be free from 
phase separation phenomena for more than one month. 
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Figure 3: % drug release from DTX-loaded SANs 
 
Results of one month stability study shows that pH of 
formulations prepared using Pluronic® F127 and 
Pluronic® F68 showed slightly decreases in pH after one 
month as compared to pH values at initial time. But not 
significant change was observed after one month storage at 
at different storage condition. According to results obtained 
for formulations F1, F2, F3    the very slight change in 
particle size was observed and did not exceed 290.3 nm 
while formulations F6, F7, F8  also shows very less changes 
in particle size and not exceed 233.4 nm. 
CONCLUSION 
The Docetaxel trihydrate loaded SANs prepared by PF127 
was found to be more stable and effective than that of 
SANs prepared by PF68. The fabrication of nanoparticulate 
drug delivery containing SANs is the need of breast cancer 
therapy. To overcome the drawbacks concern with the 
bioavailability of docetaxel trihydrate, the formulation of 
SANs delivery system was found to be best approach in the 
designing of novel controlled release drug delivery system. 
The DTX-loaded SANs was act as an potential drug carrier 
to fulfill the demand of cancer therapeutics. 
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